Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in dMMR/MSI-H Rectal Cancer
NCT04357587Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2020
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in rectal cancer, sponsored by Case Comprehensive Cancer Center. Primary endpoints: Rate of adverse events, Proportion of participants able to complete planned neoadjuvant treatment protocol and 4 more. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04357587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357587.